TY - JOUR
T1 - Neuromuscular electrical stimulation to combat cognitive aging in people with spinal cord injury
T2 - protocol for a single case experimental design study
AU - Vints, Wouter A.J.
AU - Levin, Oron
AU - van Griensven, Martijn
AU - Vlaeyen, Johan W.S.
AU - Masiulis, Nerijus
AU - Verbunt, Jeanine
AU - van Laake-Geelen, Charlotte C.M.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Introduction: Individuals with spinal cord injury (SCI) can experience accelerated cognitive aging. Myokines (factors released from muscle cells during contractions), such as brain-derived neurotrophic factor (BDNF), are thought to have beneficial effects on cognition. Neuromuscular electrical stimulation (NMES) was shown to elicit a large release of myokines. However, the effects of NMES on cognitive function have not been studied. Objective: To present the study protocol for a clinical trial evaluating the effects of NMES aimed at improving cognition and BDNF. Methods: A replicated randomized three-phases single-case experimental design (SCED) with sequential multiple baseline time series and a single-armed prospective trial will be conducted with 15 adults with chronic SCI (> 12 months after injury) above L1 neurological level undergoing 30-min quadriceps NMES, 3 days per week for 12 weeks. Main study endpoints: Primary endpoint is cognitive performance (assessed by a smartphone test) conducted three times per week during the baseline phase with random duration of 3 to 8 weeks, the intervention phase of 12 weeks, and the follow-up phase of 3 weeks after a no measurement rest period of 12 weeks. Secondary endpoints are changes in BDNF levels and cognitive performance measured before the baseline period, before and after intervention and after a 12 weeks follow-up. Conclusion: This will be the first study investigating the effects of 12 weeks NMES on both cognition and BDNF levels in individuals with SCI. The SCED results provide information on individual treatment effect courses which may direct future research. Trial registration: ClinicalTrials.gov (NCT05822297, 12/01/2023).
AB - Introduction: Individuals with spinal cord injury (SCI) can experience accelerated cognitive aging. Myokines (factors released from muscle cells during contractions), such as brain-derived neurotrophic factor (BDNF), are thought to have beneficial effects on cognition. Neuromuscular electrical stimulation (NMES) was shown to elicit a large release of myokines. However, the effects of NMES on cognitive function have not been studied. Objective: To present the study protocol for a clinical trial evaluating the effects of NMES aimed at improving cognition and BDNF. Methods: A replicated randomized three-phases single-case experimental design (SCED) with sequential multiple baseline time series and a single-armed prospective trial will be conducted with 15 adults with chronic SCI (> 12 months after injury) above L1 neurological level undergoing 30-min quadriceps NMES, 3 days per week for 12 weeks. Main study endpoints: Primary endpoint is cognitive performance (assessed by a smartphone test) conducted three times per week during the baseline phase with random duration of 3 to 8 weeks, the intervention phase of 12 weeks, and the follow-up phase of 3 weeks after a no measurement rest period of 12 weeks. Secondary endpoints are changes in BDNF levels and cognitive performance measured before the baseline period, before and after intervention and after a 12 weeks follow-up. Conclusion: This will be the first study investigating the effects of 12 weeks NMES on both cognition and BDNF levels in individuals with SCI. The SCED results provide information on individual treatment effect courses which may direct future research. Trial registration: ClinicalTrials.gov (NCT05822297, 12/01/2023).
KW - Brain-derived neurotrophic factor
KW - Chronic rehabilitation care
KW - Cognition
KW - Myokine
KW - Neuromuscular electrical stimulation
KW - Neuroplasticity
KW - Single case experimental design
KW - Spinal cord injury
UR - http://www.scopus.com/inward/record.url?scp=85195887903&partnerID=8YFLogxK
U2 - 10.1186/s12883-024-03699-9
DO - 10.1186/s12883-024-03699-9
M3 - Article
C2 - 38862912
AN - SCOPUS:85195887903
SN - 1471-2377
VL - 24
JO - BMC Neurology
JF - BMC Neurology
IS - 1
M1 - 197
ER -